NervGen Pharma (NASDAQ:NGEN) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

NervGen Pharma (NASDAQ:NGEN – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.05), Zacks reports.

NervGen Pharma Price Performance

Shares of NASDAQ:NGEN opened at $1.82 on Tuesday. The business’s fifty day moving average is $1.73. NervGen Pharma has a 52-week low of $1.28 and a 52-week high of $6.30.

Wall Street Analyst Weigh In

NGEN has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of NervGen Pharma in a research note on Monday, November 2nd. Wall Street Zen upgraded shares of NervGen Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 24th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, NervGen Pharma has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Read Our Latest Research Report on NGEN

About NervGen Pharma

(Get Free Report)

NervGen Pharma is a clinical-stage biotechnology company focused on developing treatments for nervous system injuries and diseases. The company’s research centers on ways to support nerve repair and restore function after damage to the nervous system. Its lead investigational product, NVG-291, is a peptide designed to target a protein involved in limiting nerve repair. NervGen has studied the candidate for spinal cord injury and is exploring its potential in other conditions involving nervous system damage.

Read More

Receive News & Ratings for NervGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NervGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.